What Trius Therapeutics does

Trius Therapeutics is a biopharmaceutical company founded in 2004 and headquartered in Lexington, Massachusetts, focused on the development of innovative antibiotics for life-threatening infections. The company operated as a clinical-stage therapeutics developer, advancing small-molecule antibacterial compounds through preclinical and clinical development toward regulatory approval and commercialization in the acute-care hospital setting. Its business model was the classic clinical-stage biotech archetype: raise venture capital in staged rounds, progress a lead asset through clinical trials, and either launch commercially or transact via acquisition or partnership. No product names, clinical-trial readouts, regulatory milestones, or approved assets are documented in the input data, so the specific lead compound and its development status cannot be confirmed from the available material.

The company executed a multi-year venture-funding program spanning 2006 through 2013, raising a disclosed total of approximately $99.25 million across at least five rounds. Institutional capital came from recognized biotech venture investors including Sofinnova Investments (which led the 2007 Series 2), InterWest Partners, and Versant Ventures, with earlier-stage participation from TCA Venture Group. The 2007 round of $20 million was the first major institutional event, and subsequent rounds in 2009, 2011, and 2013 reflect a sustained capital cadence consistent with advancement of a clinical asset. Leadership at the time comprised Jeffrey Stein as President & CEO, David Kabakoff as Chairman of the Board, and Craig Thompson as Chief Commercial Officer — a team structure consistent with a company preparing for either a commercial launch or a strategic exit.

Trius Therapeutics was listed on NASDAQ under ticker TSRX and is currently classified as delisted, consistent with the company having been acquired and absorbed by a larger acquirer. The original website (triusrx.com) no longer carries substantive content. No pricing, distribution, customer, partnership, or product-portfolio data is available in the input, so the company's commercial mechanics, partner ecosystem, and any approved or marketed products cannot be characterized from this dataset. The 1,001-5,000 employee headcount figure in the firmographic data is inconsistent with a clinical-stage biotech of this profile and funding scale, and should be treated with low confidence.

Name

Trius Therapeutics

Website

https://triusrx.com

Company type

Private

Founded year

2004

Headcount range

1,001–5,000 employees

Short description

Trius Therapeutics is a biopharmaceutical company founded in 2004, headquartered in Lexington, Massachusetts, that developed innovative antibiotics for life-threatening infections. It operated as a clinical-stage biotech and is now delisted following acquisition.

Ownership category

akta.pro rank

Product category

Infectious Disease Pharmaceuticals

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

akta.pro secondary industry

Microbiome Modulating Small Molecules & Antibiotic Alternatives (HLAAAFAG)

Keywords

• Antibiotic drug development
• Infectious disease therapeutics
• Novel antibiotic compounds
• Antimicrobial pharmaceutical research
• Life-threatening infection treatment

Headquarters

HQ city

Lexington

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Core offering

Trius Therapeutics develops innovative antibiotics for the treatment of life-threatening bacterial infections. The company focuses on discovering and advancing novel antimicrobial compounds to address serious infectious diseases, with emphasis on therapies for drug-resistant pathogens.

Differentiator

Problem solved

Functional benefit

Products and services

• Innovative antibiotic therapies for life-threatening infections

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves6 records

Expansion highlights4 records

Emerging players

• Motif Bio: Clinical-stage antibiotics developer (iclaprim) targeting acute bacterial skin infections. Comparable in single-asset, late-stage antibiotics focus, though smaller and UK-listed.

Direct peers

• Achaogen: Clinical-stage antibiotics developer targeting multi-drug resistant gram-negative infections. Comparable in therapeutic focus, stage of development, and capital intensity, with a similar NASDAQ-listed trajectory.
• Nabriva Therapeutics: Developer of lefamulin, a first-in-class pleuromutilin antibiotic for community-acquired bacterial pneumonia. Comparable in antibiotic specialty positioning, single-asset development model, and hospital-channel go-to-market.
• Optimer Pharmaceuticals: Late-stage antibiotics developer focused on hospital infections (fidaxomicin/DIFICID for C. difficile). Direct comparable in business model — single-asset, hospital-channel antibiotic launches with similar regulatory and stewardship dynamics.
• Melinta Therapeutics: Developer of delafloxacin and other antibiotics targeting serious bacterial infections. Direct comparable as a specialty antibiotics commercial-stage company with similar hospital-channel positioning.
• Tetraphase Biosciences: Developed eravacycline, a synthetic tetracycline antibiotic for complicated intra-abdominal and urinary tract infections. Closely comparable in clinical-stage antibiotic development, regulatory pathway, and commercial channel.
• Paratek Pharmaceuticals: Developer of tetracycline-class antibiotics (omadacycline, sarecycline) targeting serious community-acquired infections. Directly comparable in therapeutic focus on differentiated antibiotics against resistant pathogens.
• Cempra: Developed solithromycin for community-acquired bacterial pneumonia and fusidic acid for acute bacterial skin infections. Closely comparable single-asset antibiotics developer with similar regulatory pathway and hospital/specialty channel dynamics.

Broad incumbents

• Merck & Co. (Cubist successor): Acquired Cubist Pharmaceuticals and inherited its antibiotics franchise. Relevant incumbent comparator for hospital antibiotics commercial dynamics and a key benchmark for strategic-exit valuation in this category.
• Cubist Pharmaceuticals: Established hospital-antibiotics company that was a direct strategic acquirer in the space and built its franchise around daptomycin. Highly comparable to Trius as the lead acquirer/integrator of innovative gram-positive antibiotics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/cubistbiopharma
• Facebookfacebook.com/merckbewell

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Trius Therapeutics